
zzso zzso is found in 50% to zzso of zzso and the novel agents zzso and zzso that inhibit the zzso zzso achieve a remarkable clinical response zzso However, as might be expected, acquired clinical resistance to these agents arises in most melanoma zzso zzso resistance that arises in zzso in tumor matched short-term cultures or in zzso in melanoma cell lines is not caused by acquisition of secondary zzso in zzso but rather is caused by zzso zzso growth factor zzso zzso zzso or zzso which results in resistance or sensitivity to zzso protein zzso zzso zzso zzso zzso zzso zzso In this study, we define a targeted zzso strategy to overcome zzso resistance in melanoma cell lines or short-term culture where the resistance is driven by zzso zzso achieving synergistic growth zzso and zzso zzso zzso zzso cell lines show dual zzso zzso and zzso zzso and their growth zzso responses to specific small zzso zzso correlated with zzso zzso and zzso zzso zzso zzso of zzso zzso and the zzso axis led to functionally significant rebound zzso illustrating a robust and dynamic network zzso Combined zzso zzso zzso zzso and zzso zzso suppressed both immediate early and delayed zzso zzso resulting in a highly synergistic growth zzso response but less efficient zzso zzso In contrast, the combination of zzso zzso and zzso zzso consistently triggered zzso in a highly efficient zzso Together, our findings offer a rational strategy to guide clinical testing in zzso zzso of patients who zzso during treatment with zzso zzso 

